Psychosomatic, Physical Activity or Both for Post-covid19 Syndrom
Launched by HANNOVER MEDICAL SCHOOL · Sep 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best ways to help people who are experiencing fatigue after recovering from COVID-19, a condition known as Post-COVID-19 Syndrome. Researchers want to find out if therapy focused on talking (psychotherapy), exercise programs, or a combination of both can improve fatigue levels in patients. The trial will involve three different groups: one group will receive psychotherapy, another will participate in physical rehabilitation, and the third group will get both types of treatment. The goal is to see which approach works best for different patients over a period of three months, followed by an evaluation after another three months without treatment.
To be eligible for this trial, participants must be at least 18 years old, have been diagnosed with Post-COVID-19 Syndrome through a positive test, and score 22 or higher on a fatigue assessment scale. However, individuals who are currently involved in another study, have other medical conditions that could explain their fatigue, or have serious mental health issues are not eligible to participate. Throughout the trial, participants can expect to attend online therapy sessions lasting 50 minutes every two weeks, and researchers will also look into who benefits most from each type of therapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged over 18 and
- • diagnosed post-Covid-19 syndrome: (positive PCR or antibody test) and Fatigue Assessment Scale (FAS) ≥ 22 points
- Exclusion Criteria:
- • Current participation in another intervention study
- • Illnesses or functional disorders that potentially explain the fatigue symptoms otherwise
- • Any illness or impairment that the examining physician judges to preclude participation in a physical training intervention
- • Suicidality or severe mental illness (e.g. mania, acute phase of schizophrenia) that requires acute treatment.
About Hannover Medical School
Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannover, , Germany
Hannover, Lower Saxony, Germany
Patients applied
Trial Officials
Uwe Tegtbur
Principal Investigator
Hannover Medical School, Institute for Sports Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported